Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Common Equity (2019 - 2025)

Maxcyte (MXCT) has disclosed Common Equity for 7 consecutive years, with $171.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 16.85% to $171.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $171.5 million through Dec 2025, down 16.85% year-over-year, with the annual reading at $171.5 million for FY2025, 16.85% down from the prior year.
  • Common Equity for Q4 2025 was $171.5 million at Maxcyte, down from $180.3 million in the prior quarter.
  • The five-year high for Common Equity was $264.1 million in Q3 2021, with the low at $78.8 million in Q2 2021.
  • Average Common Equity over 5 years is $213.9 million, with a median of $229.3 million recorded in 2023.
  • The sharpest move saw Common Equity soared 691.26% in 2021, then dropped 16.85% in 2025.
  • Over 5 years, Common Equity stood at $262.9 million in 2021, then fell by 3.4% to $254.0 million in 2022, then fell by 8.58% to $232.2 million in 2023, then decreased by 11.16% to $206.3 million in 2024, then decreased by 16.85% to $171.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $171.5 million, $180.3 million, and $190.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.